Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
drug market access
Should there be a different review of NICE as part of a successor PPRS?
The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Eric Low shares his views on why hurdles remain to new drug access.
Though they can reduce the costs of health care, biosimilars still face challenges to access.
Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Examining the true impact of a positive health technology assessment (HTA).
The steps required for successful market access.
Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.